The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ed Woo - Ascendiant Capital Markets - Analyst
: Yes. Thank you for taking my question. My question is on PTSD additional indication. Do you anticipate starting filing the IND this quarter or the
next quarter in order to start a trial by the fourth quarter?
Question: Ed Woo - Ascendiant Capital Markets - Analyst
: Great. And then in terms of how large the possible trial can be, do you have any indications of how big it may be?
Question: Ed Woo - Ascendiant Capital Markets - Analyst
: Great. And then my last question is: in terms of what you guys have learned with your current study, do you think that you'll be able to use any of
that data in order facilitate the trial possibly being easier or being able to go faster?
Question: Ed Woo - Ascendiant Capital Markets - Analyst
: Great. Well, thanks for giving me the answer, and I wish you guys good luck. Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 16, 2023 / 12:30PM, NRXP.OQ - Q1 2023 NRX Pharmaceuticals Inc Earnings Call
Question: Jason Kolbert - Dawson James - Analyst
: Hi, guys. Congratulations on the progress.
Question: Jason Kolbert - Dawson James - Analyst
: Good morning. Can you talk a little bit about the dynamics of actually enrolling these bipolar depressed patients with suicide ideology? How do
they come to you? How do they end up being referred into the trial? What's the entry criteria on these patients? And then I want to talk a little bit
about what are the endpoints of the trial.
Question: Jason Kolbert - Dawson James - Analyst
: Yeah. I mean, I can appreciate the infrastructure required to accomplish all of that. And given where you are, how confident are you in the velocity
of enrollment that supports that statement that you're funded through kind of the data read at the end of the year?
Question: Jason Kolbert - Dawson James - Analyst
: Okay. Thank you. And can you break down for me -- just review with me the primary endpoint and what exactly the components of it are that are
measured?
Question: Jason Kolbert - Dawson James - Analyst
: Really appreciate the update. Thank you. We'll be watching the progress.
| 
